title: Letter: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
authors.affiliation: Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: J-F
authors.initials: JF
authors.lastname: Jiang
authors.affiliation: Department of Medical Affairs, ZiBo Hospital of Integrated Traditional Chinese and Western Medicine, Zibo, China.
authors.forename: J
authors.initials: J
authors.lastname: Sun
authors.affiliation: Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: J
authors.initials: J
authors.lastname: Shi
authors.affiliation: Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: X
authors.initials: X
authors.lastname: Liu
mesh_terms: D006528:Carcinoma, Hepatocellular; D004279:DNA, Viral; D006509:Hepatitis B; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006513:Hepatitis B e Antigens; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000276:immunology; D006801:Humans; D008113:Liver Neoplasms
chemical_list: D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens